For Those on Watch, Hope Springs Eternal as Hair Trials Inch Along

5/18/12Follow @bvbigelow

Waiting for the biotech industry to advance new treatments for male pattern baldness (as well as female hair loss) might seem about as exciting as watching hair grow. But some people have a lot of skin in the game, if you know what I mean.

More than just a few people, actually. San Diego’s Histogen estimates that hair loss affects some 40 million men and 21 million women in the United States alone. Histogen, which has been developing a bio-engineered treatment for stimulating hair growth, says less than 7 percent seek treatment for their hair loss “due to the limitations of available options.”

For these people, any incremental improvement in hair growth can be thrilling—even life-changing—which helps explain a burst of enthusiasm we’ve noticed in recent days in messages penned below a 2011 article about Boston-based Follica on the Xconomy Boston website. With close to 1,500 comments posted over the past 14 months our readers have shown no loss for words, making this one article a defacto online message board and a virtual support group for the follically challenged.

As I reported in 2010, few life sciences companies have gotten as much mileage from a pilot trial that enrolled two dozen patients as Histogen has for its much-anticipated treatment. The company says its formulation consists of proteins, including growth factor molecules, secreted by human fibroblast cells grown in a laboratory culture. The concoction is injected just below the scalp.

Over the past week, gentle and not so-gentle visitors to the Follica comment page have seized on the early results of Histogen’s latest experimental trial, which Histogen CEO Gail Naughton presented a week ago in Raleigh, NC, during the annual meeting of the Society for Investigative Dermatology. Naughton gave an oral summary of the data on May 11 and presented a poster the following day on “Stimulation of hair growth in humans by cell-secreted proteins.”

The data has not yet been published in a peer-reviewed scientific journal, according to a Histogen spokeswoman. “We are not releasing an announcement at this time,” she adds.

Yet Histogen has summarized its early findings on its website, where a PDF copy of the May 12 poster also can be downloaded. The company says 56 patients were enrolled in an early stage clinical trial (conducted in the Philippines) of its Hair Stimulating Complex (HSC). The patients received eight injections of HSC (double the number of injections in the 2010 pilot study), with a repeat dose at week six. The treatment was well-tolerated and no study-related adverse effects were reported. At 12 weeks, the patients showed a 46.5 percent increase in total hair count above and beyond the “statistically significant” improvement in hair growth and density that was reported at 12 weeks in the 2010 pilot study.

An additional physician-sponsored investigational new drug (IND) study is being conducted in the United States by Dr. Craig Ziering with 10 subjects, both men and women. Histogen says the study was initiated to evaluate the safety and efficacy of HSC, and also produced “hair growth effects in patients with diffuse hair loss.”

The company’s disclosure triggered a flurry of hopeful comments on Xconomy, beginning with a post by “Hope for Baldness,” who linked to Histogen’s PDF file and wrote, “I always read comments here and never post but I was force to post this. Very exciting!!!!! The cure is near for real. No bullshit!!!!!!! I have proof!!!!!!”

You could say they got their dander up. But Histogen’s findings barely scratch the surface. These are only partial results from an early stage, phase I/II trial. Even if the company continues to show positive results, it will be years before Histogen could bring its HSC treatment to market.

In response to my query about Histogen’s timeline for development, the company passed along an email from CEO Naughton:

“We anticipate pivotal trials in the U.S. or Asia will begin next year. As it is Histogen’s business model to bring each of its product applications to market through partnerships with leaders in different industries and geographic locations, strategy for future clinical trials of HSC will be largely dependent upon the regions of interest for such partners. We hope to have an NDA [new drug application] filed in the U.S. or Asia before the end of 2015.”

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

By posting a comment, you agree to our terms and conditions.

  • McJ

    And who says Xconomy don’t pay attention to their Follica readers!? Sooo, what do Follica make of all this Histogen business? More to the point, what do Follica have to say for themselves? Still keeping mum as they say? You Xconomy guys keep asking right?

  • Sjdfksd

    FUCK FDA

  • Herzog

    I’m glad we can move on from a Follica based thread to a Histogen based thread. We’ll see them patenting HSC in two years. Right on schedule to their projections back in 2010.
    This is the first time a company hasn’t re-upped its “in 5 years” projection. We’re actually making progress on a timeline.

    Wow. Carry on Histogen

  • Guest

    Woohoo!  That means by the time my dotcom becomes profitable, I can re-grow my hair and marry a girl in her 20s.  I love the internet!

  • julian

    Well said, Bruce Bigelow: “Waiting for the biotech industry to advance new treatments for male pattern baldness (as well as female hair loss) might seem about as exciting as watching hair grow.”

  • Alex178

    It seems that Bruce Bigelow succeed in killing this great forum.
    He must be proud some tried hard but Bruce did it.
    Very sad.

  • rev

    Subscribed

  • Alex178

    Finally it seems that some decided to ignore this new thread.
    Indeed the previous thread is starting again.

    I just hope hope that everyone will come back to share their discoveries.
     
    More people means more research on the web and more informations.

    • Alex178

       By the old thread I mean “Follica Sheds More Light on Hair Re-Growth Invention”

  • McJ

    Hey Bruce,

    I and some others on the other thread (ok, mostly me) do wonder if you good folks at Xconomy keep asking Follica for an update. So, you do ask right? Even a ‘nothing to report’ report would be kinda nice. At least so we know Follica are still active and such.

    Things are awfully quiet at the moment and we can’t help but wonder.

    Thanks for reading (assuming you actually read these)